CoChat

Cardiovascular Protective Properties of GLP-1 Receptor Agonists: More than Just Diabetic and Weight Loss Drugs

Open access

The DOI matches its Crossref record; 177 of the 178 references it cites were found in a registry or an index.

Abstract

Owing to their potent glucose-lowering efficacy and substantial weight loss effects, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are now considered part of the frontline therapeutic options to treat both type 2 diabetes mellitus and nondiabetic overweight/obesity. Stemming from successful demonstration of their cardiometabolic modulation and reduction of major adverse cardiovascular events in clinical outcome trials, GLP-1 RAs have since been validated as agents with compelling cardiovascular protective properties. Studies spanning from the bench to preclinical and large-scale randomised controlled trials have consistently corroborated the cardiovascular benefits of this pharmacological class. Most notably, there is converging evidence that they exert favourable effects on atherosclerotic ischaemic endpoints, with preclinical data indicating that they may do so by directly modifying the burden and composition of atherosclerotic plaques. This narrative review examines the underlying pharmacology and clinical evidence behind the cardiovascular benefits of GLP-1 RAs, with particular focus on atherosclerotic cardiovascular disease. It also delves into the mechanisms that underpin their putative plaque-modifying actions, addresses existing knowledge gaps and therapeutic challenges and looks to future developments in the field, including the use of combination incretin agents for diabetes and weight loss management.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm13164674

Cites

177 of 177 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Intracellular signalling pathways induced by GLP-1 RA binding to GLP-1R in pancreatic β cells. These result in attenuation of endoplasmic reticulum (ER) stress (pink), inhibition of apoptosis (purple), increased insulin exocytosis (green), β cell proliferation (yellow) and improved glucose handling and homeostasis (white). AC: adenylyl cyclase, AKT/PKB: protein kinase B, AMPK: adenosine monophosphate-activated protein kinase, ATF4: activating transcription factor 4, ATP: adenosine triphosphate, B-raf: serine/threonine–protein kinase B-raf, Ca2+: calcium ions, cAMP: cyclic adenosine monophosphate, CREB: cAMP-response element binding protein, c-Src: tyrosine–protein kinase Src, DAG: diacylglycerol, dephosph-eIF2α: dephosphorylated eukaryotic initiation factor 2α, EGFR: epidermal growth factor receptor, Epac2: exchange protein activated by cAMP 2, ERK1/2: extracellular signal-regulated kinase 1/2, FOXO1: forkhead box protein O1, GLP-1R: glucagon-like peptide 1 receptor, GLP-1 RA: glucagon-like peptide 1 receptor agonist, HIF-α: hypoxia-inducible factor 1-α, IGF1R: insulin-like growth factor 1 receptor, IGF2: insulin-like growth factor 2, IP3: inositol 1,4,5-trisphosphate, IP3R: inositol 1,4,5-trisphosphate receptor, Irs2: insulin receptor substrate 2, mTOR: mammalian target of rapamycin, PDX-1: pancreatic and duodenal homeobox 1, PI3K: phosphoinositide 3-kinase, PIP2: phosphatidylinositol (4,5)-diphosphate, PLC: phospholipase C, PKA: protein kinase A, Rap1: Ras-proximate-1, RyR: ryanodine receptor, SUR1: sulfonylurea receptor 1, TCF7L2: transcription factor 7 like 2, VGCC: voltage-gated calcium channel, Wnt: wingless-related integration site. Created with BioRender.com.
Figure 1 Intracellular signalling pathways induced by GLP-1 RA binding to GLP-1R in pancreatic β cells. These result in attenuation of endoplasmic reticulum (ER) stress (pink), inhibition of apoptosis (purple), increased insulin exocytosis (green), β cell proliferation (yellow) and improved glucose handling and homeostasis (white). AC: adenylyl cyclase, AKT/PKB: protein kinase B, AMPK: adenosine monophosphate-activated protein kinase, ATF4: activating transcription factor 4, ATP: adenosine triphosphate, B-raf: serine/threonine–protein kinase B-raf, Ca2+: calcium ions, cAMP: cyclic adenosine monophosphate, CREB: cAMP-response element binding protein, c-Src: tyrosine–protein kinase Src, DAG: diacylglycerol, dephosph-eIF2α: dephosphorylated eukaryotic initiation factor 2α, EGFR: epidermal growth factor receptor, Epac2: exchange protein activated by cAMP 2, ERK1/2: extracellular signal-regulated kinase 1/2, FOXO1: forkhead box protein O1, GLP-1R: glucagon-like peptide 1 receptor, GLP-1 RA: glucagon-like peptide 1 receptor agonist, HIF-α: hypoxia-inducible factor 1-α, IGF1R: insulin-like growth factor 1 receptor, IGF2: insulin-like growth factor 2, IP3: inositol 1,4,5-trisphosphate, IP3R: inositol 1,4,5-trisphosphate receptor, Irs2: insulin receptor substrate 2, mTOR: mammalian target of rapamycin, PDX-1: pancreatic and duodenal homeobox 1, PI3K: phosphoinositide 3-kinase, PIP2: phosphatidylinositol (4,5)-diphosphate, PLC: phospholipase C, PKA: protein kinase A, Rap1: Ras-proximate-1, RyR: ryanodine receptor, SUR1: sulfonylurea receptor 1, TCF7L2: transcription factor 7 like 2, VGCC: voltage-gated calcium channel, Wnt: wingless-related integration site. Created with BioRender.com.CC BY · PubMed Central
Figure 2 Summary of the cardiometabolic benefits of GLP-1 RA therapy. Green upward arrow: increases; Red downward arrow, decreases. Created with BioRender.com.
Figure 2 Summary of the cardiometabolic benefits of GLP-1 RA therapy. Green upward arrow: increases; Red downward arrow, decreases. Created with BioRender.com.CC BY · PubMed Central
Figure 3 Putative Molecular Mechanisms for Anti-Atherogenic Effects of GLP-1 RAs. ABCA1: ATP-binding cassette transporter A1, ANG-II: angiotensin-II, AMPK: AMP-activated protein kinase, ANP: atrial natriuretic peptide, Arg-1: arginase-1, ATF6: cyclic AMP-dependent transcription factor-6, CCL2: C–C motif chemokine ligand 2, CCR7: C-C chemokine receptor type 7, CD62p: P-selectin, CD163+ Mac: cluster of differentiation 163+ macrophage, cGMP: cyclic guanine monophosphate, CRP: C-reactive protein, eNOS: endothelial nitric oxide synthase, FOXO3a: forkhead transcription factor O subfamily member 3a, HTN: hypertension, iNOS: inducible nitric oxide synthase, IFN-γ: interferon-γ, IL-1β: interleukin-1β, IL-6: interleukin-6, IL-10: interleukin-10, IRE1α: inositol-requiring enzyme 1, JNK: c-Jun N-terminal kinase, KLF2: Krüppel-like factor 2, LDL-C: low-density lipoprotein cholesterol, MAPK: mitogen-activated protein kinase, Mφ: macrophage, M1: M1 macrophage, M2: M2 macrophage, MMP: matrix metalloproteinase, MCP-1: monocyte chemoattractant protein-1, NLRP3: nucleotide-binding domain (NOD)-like receptor protein 3, NO: nitric oxide, PERK: protein kinase R-like ER kinase, PKG: protein kinase G, RAGE: receptor for advanced glycation end-products, ROS: reactive oxygen species, SIRT1: sirtuin 1, STAT1: signal transducer and activator of transcription 1, STAT3: signal transducer and activator of transcription 3, TAG: triacylglyceride, TIMP: tissue inhibitor of metalloproteinases, TNF-α: tumour necrosis factor-α, VASP: vasodilator-stimulated phosphoprotein, VCAM1: vascular cell adhesion protein 1, VSMC: vascular smooth muscle cell. Green upward arrow, increases. Red downward arrow, reduces. Red cross, inhibits. Created with BioRender.com.
Figure 3 Putative Molecular Mechanisms for Anti-Atherogenic Effects of GLP-1 RAs. ABCA1: ATP-binding cassette transporter A1, ANG-II: angiotensin-II, AMPK: AMP-activated protein kinase, ANP: atrial natriuretic peptide, Arg-1: arginase-1, ATF6: cyclic AMP-dependent transcription factor-6, CCL2: C–C motif chemokine ligand 2, CCR7: C-C chemokine receptor type 7, CD62p: P-selectin, CD163+ Mac: cluster of differentiation 163+ macrophage, cGMP: cyclic guanine monophosphate, CRP: C-reactive protein, eNOS: endothelial nitric oxide synthase, FOXO3a: forkhead transcription factor O subfamily member 3a, HTN: hypertension, iNOS: inducible nitric oxide synthase, IFN-γ: interferon-γ, IL-1β: interleukin-1β, IL-6: interleukin-6, IL-10: interleukin-10, IRE1α: inositol-requiring enzyme 1, JNK: c-Jun N-terminal kinase, KLF2: Krüppel-like factor 2, LDL-C: low-density lipoprotein cholesterol, MAPK: mitogen-activated protein kinase, Mφ: macrophage, M1: M1 macrophage, M2: M2 macrophage, MMP: matrix metalloproteinase, MCP-1: monocyte chemoattractant protein-1, NLRP3: nucleotide-binding domain (NOD)-like receptor protein 3, NO: nitric oxide, PERK: protein kinase R-like ER kinase, PKG: protein kinase G, RAGE: receptor for advanced glycation end-products, ROS: reactive oxygen species, SIRT1: sirtuin 1, STAT1: signal transducer and activator of transcription 1, STAT3: signal transducer and activator of transcription 3, TAG: triacylglyceride, TIMP: tissue inhibitor of metalloproteinases, TNF-α: tumour necrosis factor-α, VASP: vasodilator-stimulated phosphoprotein, VCAM1: vascular cell adhesion protein 1, VSMC: vascular smooth muscle cell. Green upward arrow, increases. Red downward arrow, reduces. Red cross, inhibits. Created with BioRender.com.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 72

Metadata

Authors
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J.
Affiliations
  • Flinders University (AU)
  • South Australian Health and Medical Research Institute (AU)
  • The University of Adelaide (AU)
  • Central Adelaide Local Health Network (AU)
Corresponding author
Psaltis, Peter J.
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2024-08-09
Volume
13
Issue
16
Pages
4674
ISSN
2077-0383 (ISSN-L)
OpenAlex
W4401456648
Cited by
66
References
178
Citations by year
2026: 32 · 2025: 31 · 2024: 3
FWCI
3.87
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
National Heart Foundation of Australia (FLF106656)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, cardioprotection, atherosclerotic cardiovascular disease, type 2 diabetes, obesity, weight loss, incretin-based therapy, major adverse cardiovascular events, cardiometabolic effects

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.